- Raised $2.5 million in seed investment; Won > $6 million in grants from US DoD, NIH, and NSF
- Huge markets and financial opportunities: 3.1 billion USD tuberculosis & 20 billion USD lung cancer diagnostics in 2022
- Our products – low cost, accurate, non-invasive, non-lab dependent lung cancer & tuberculosis tests
- Our CE Mark is targeted for 2022, allowing product distribution in EU countries; clear path to FDA clinical trials
Pace Diagnostics is an emerging biotechnology company focused on the research, development, licensing, manufacturing and marketing of cutting-edge human diagnostics. We are developing novel, first to market, low cost, accurate, early detection lung cancer and tuberculosis point of care diagnostics, non-lab dependent with result in less than 30 minutes.
Our ambition is to solve a multi-trillion dollar per year problem that causes over 4 million deaths per year. Current clinical diagnostics for tuberculosis (TB) and lung cancer are too expensive and too invasive for large scale population testing. Our vision is to be the dominant provider of early tuberculosis and lung cancer detection for mass populations. By testing large populations, we will detect many cases earlier, and early detection for large population saves many more lives.